Mavixan

Rizatriptan, the active ingredient in Mavixan, is a Triptan (5-HT1B/1D receptor agonist) presented as an oral tablet for oral use. It is indicated for the acute treatment of migraine attacks in adults. GNH USA supplies Mavixan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mavixan belongs to the triptan class and is used to treat migraine‑related conditions. - Migraine with aura: provides rapid relief of headache pain and associated symptoms. - Migraine without aura: reduces headache severity and duration. - Acute migraine attacks: aborts the attack when taken at the first sign of headache.

Rizatriptan may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Chest discomfort or tightness - Tingling or numbness in fingers or toes - Nausea or stomach upset - Dizziness or light‑headedness - Fatigue or drowsiness - Dry mouth

Serious or Rare Side Effects: - Coronary vasospasm or myocardial ischemia - Serotonin syndrome, especially with other serotonergic agents - Severe allergic reactions (anaphylaxis, angioedema) - Hypertension or sudden increase in blood pressure - Stroke or transient ischemic attack - Severe abdominal pain or vomiting

Before prescribing Mavixan, clinicians should evaluate patient history and potential risk factors. - Cardiovascular disease: avoid in patients with coronary artery disease or uncontrolled hypertension. - Hemiplegic or basilar migraine: contraindicated due to risk of cerebrovascular events. - Concomitant serotonergic drugs: assess risk of serotonin syndrome. - Pregnancy and lactation: use only if potential benefit justifies potential risk; data are limited. - Storage: Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Rizatriptan can interact with several medication classes, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of severe hypertension and serotonin syndrome. - Other triptans or ergot derivatives: additive vasoconstrictive effects. - Selective serotonin reuptake inhibitors (SSRIs) / serotonin‑norepinephrine reuptake inhibitors (SNRIs): increased serotonin toxicity.

Moderate Interactions (Monitor Closely): - Strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise rizatriptan plasma levels. - Antihypertensive agents: possible additive blood pressure lowering. - Oral contraceptives: may slightly increase migraine frequency; monitor efficacy.